BioWorld Asia

Sep. 25, 2002

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International) Read More

Neuro3d Raises EUR20M Privately To Fund Work In CNS Disorders

BCLC Says BRCA1 Increases Risk Of Other Cancers In Women

Modex, IsoTis Plan To Merge Programs In Orthopedics, Skin

EU Urges Use Of Biotechnology In And From Developing World

European Parliament Aims To Tighten GM Trade Rules

Eirx Pharma Formed Through Three-Way Anglo-Irish Merger

Cardion Closes EUR10M Financing To Fund CRB-15, Stem Cell Work

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

Zentaris, Access Oncology Enter $30M Alliance For Cancer Drug

Other News To Note

Genset Shareholders Accept Bid From Serono; Integration Begins

Today's news in brief

BioWorld

BioWorld briefs for Dec. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 22, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.